Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XOMA licenses technology to Diagnostic Products:

This article was originally published in Clinica

Executive Summary

XOMA has licensed to Diagnostic Products Corporation technology that uses lipopolysaccharide binding protein (LBP) technology which it will use to develop automated tests to detect systemic exposure to bacteria and endotoxin. Such conditions include sepsis and infectious complications of surgery and trauma. DPC has already developed automated tests for the early detection of sepsis and related infections. It claims the new technology may result in earlier diagnosis. XOMA has already licensed the LBP technology to Biosite Diagnostics to make and sell point-of-care diagnostics in the US and to SRL to make central lab tests in Japan.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel